Department of Rheumatology, AP-HP Henri Mondor Hospital, Creteil Cedex, France.
Department of Rheumatology, Nord Franche-Comté Hospital, Belfort, France.
Cartilage. 2021 Dec;13(1_suppl):1548S-1556S. doi: 10.1177/1947603520954509. Epub 2020 Sep 10.
Up to 50% of patients with symptomatic knee osteoarthritis (OA) present with neuropathic pain (NP) features. We assessed the impact of NP according to DN4 (Douleurs Neuropathiques 4 questions) score on the response to intra-articular (IA) hyaluronic acid (HA) injections and the effects of HA injections on NP.
We conducted a analysis from a multicenter, randomized, double-blind, noninferiority trial comparing the efficacy of 2 HA in symptomatic knee OA at 24 weeks. At baseline, demographic, anthropometric, radiologic data, and symptoms were recorded. The symptomatic effect of HA was assessed by VAS pain, patient global assessment (PGA), WOMAC, DN4, and OMERACT-OARSI response.
A total of 187 patients were included. NP according to DN4 score was present in 20 patients (10.7%) at baseline. Most common positive DN4 items were tingling (36.9%) and burning (36.4%). NP was associated with WOMAC pain score ( = 0.02). The presence of NP at baseline did not affect the symptomatic improvement after HA injections according to the VAS pain ( = 0.71), PGA ( = 050), WOMAC pain ( = 0.89), WOMAC function ( = 0.52), and rate of OMERACT-OARSI responders ( = 0.21). The prevalence of patients with NP decreased by 50% ( = 10) at 24 weeks after HA injections. Most improved DN4 items were itching (90%), hypoesthesia to pinprick (88%), and burning (50%).
In our study, NP was associated with pain severity, but did not influence the response to IA HA. On the other hand, HA injections reduced some NP features, especially itching, sting hypoesthesia, and burning.
多达 50%的有症状膝骨关节炎(OA)患者出现神经病理性疼痛(NP)特征。我们根据 DN4(4 个神经病理性疼痛问题)评分评估 NP 对关节内(IA)透明质酸(HA)注射反应的影响,以及 HA 注射对 NP 的影响。
我们对一项多中心、随机、双盲、非劣效性试验进行了 分析,该试验比较了 2 种 HA 在 24 周时对有症状膝 OA 的疗效。在基线时,记录了人口统计学、人体测量学、影像学数据和症状。通过 VAS 疼痛、患者整体评估(PGA)、WOMAC、DN4 和 OMERACT-OARSI 反应评估 HA 的症状缓解效果。
共纳入 187 例患者。基线时,20 例(10.7%)患者存在 NP,根据 DN4 评分。最常见的阳性 DN4 项目是刺痛(36.9%)和烧灼感(36.4%)。NP 与 WOMAC 疼痛评分相关( = 0.02)。基线时存在 NP 并不影响 HA 注射后 VAS 疼痛( = 0.71)、PGA( = 050)、WOMAC 疼痛( = 0.89)、WOMAC 功能( = 0.52)和 OMERACT-OARSI 应答者的比例( = 0.21)的症状改善。HA 注射 24 周后,NP 患者的患病率下降了 50%( = 10)。DN4 评分改善最明显的项目是瘙痒(90%)、刺痛觉减退(88%)和烧灼感(50%)。
在我们的研究中,NP 与疼痛严重程度相关,但不影响 IA HA 的反应。另一方面,HA 注射减少了一些 NP 特征,特别是瘙痒、刺痛觉减退和烧灼感。